Jeil Pharm Asset Resilience Ratio
Jeil Pharm asset resilience ratio. Jeil Pharm (002620) has an Asset Resilience Ratio of 2.78% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 002620 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Jeil Pharm (2011–2025)
Asset resilience ratio of Jeil Pharm from 2011 to 2025. This chart shows how Jeil Pharm's Asset Resilience Ratio has changed over time. Read Jeil Pharm balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Jeil Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 002620 total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩24.81 Billion | 2.78% |
| Total Liquid Assets | ₩24.81 Billion | 2.78% |
Asset Resilience Insights
- Limited Liquidity: Jeil Pharm maintains only 2.78% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Jeil Pharm Industry Peers by Asset Resilience Ratio
Compare Jeil Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Jeil Pharm Asset Resilience Ratio by Year (2011–2025)
Jeil Pharm asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for Jeil Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.64% | ₩23.12 Billion ≈ $15.67 Million |
₩876.66 Billion ≈ $594.10 Million |
+0.83pp |
| 2024-12-31 | 1.80% | ₩16.06 Billion ≈ $10.89 Million |
₩890.43 Billion ≈ $603.43 Million |
-0.71pp |
| 2023-12-31 | 2.51% | ₩22.09 Billion ≈ $14.97 Million |
₩880.00 Billion ≈ $596.36 Million |
+0.36pp |
| 2022-12-31 | 2.15% | ₩18.64 Billion ≈ $12.63 Million |
₩865.68 Billion ≈ $586.66 Million |
+0.06pp |
| 2021-12-31 | 2.09% | ₩18.64 Billion ≈ $12.63 Million |
₩892.42 Billion ≈ $604.78 Million |
+0.99pp |
| 2020-12-31 | 1.10% | ₩9.78 Billion ≈ $6.63 Million |
₩887.40 Billion ≈ $601.37 Million |
+0.05pp |
| 2019-12-31 | 1.05% | ₩8.88 Billion ≈ $6.01 Million |
₩846.47 Billion ≈ $573.64 Million |
+0.65pp |
| 2018-12-31 | 0.40% | ₩3.69 Billion ≈ $2.50 Million |
₩920.09 Billion ≈ $623.53 Million |
-2.05pp |
| 2017-12-31 | 2.45% | ₩4.84 Billion ≈ $3.28 Million |
₩197.59 Billion ≈ $133.90 Million |
+1.81pp |
| 2016-12-31 | 0.64% | ₩3.15 Billion ≈ $2.14 Million |
₩491.98 Billion ≈ $333.41 Million |
-0.06pp |
| 2015-12-31 | 0.70% | ₩3.10 Billion ≈ $2.10 Million |
₩445.17 Billion ≈ $301.68 Million |
-1.86pp |
| 2012-12-31 | 2.56% | ₩9.99 Billion ≈ $6.77 Million |
₩390.77 Billion ≈ $264.82 Million |
-5.11pp |
| 2011-12-31 | 7.67% | ₩29.44 Billion ≈ $19.95 Million |
₩384.13 Billion ≈ $260.32 Million |
-- |
About Jeil Pharm
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms i… Read more